Experts Speculate On Cause Of Neurological Damage in FAAH Inhibitor Study
This article was originally published in Scrip
Executive Summary
The French expert committee set up to look at the preclinical data on Bial's FAAH inhibitor, BIA 10-2474, says that the adverse events that led to the death of one volunteer and the hospitalization of several others in a Phase I study of the drug could be attributable either to an action of the compound beyond FAAH inhibition or to the effects exerted by a metabolite.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.